{"schema_version":"1.0","hypothesis_id":38263,"triple":{"drug":"secukinumab","drug_canonical":"secukinumab","mediator":"IL-17A","mediator_canonical":"il-17a","outcome":"neural progenitor proliferation","outcome_canonical":"neural progenitor proliferation"},"domain":{"domain":"cross_domain","source":"rheumatoid_arthritis","target":"epilepsy"},"provenance_completeness":"partial_backfill","completeness_notes":"Backfilled retroactively from DB state on 2026-05-13. The pipeline_run this row references was created by the backfill script, not by the actual generation orchestrator. Source papers, claims, scoring, and embedding config are recovered; generation-time metadata (exact git commit at gen time, host, exact command) is not recoverable.","source_papers":[{"doi":"10.3389/fnmol.2022.917598","pmid":"35875667","year":2022,"roles":["mediator_outcome"],"title":"Interleukin-17A Mediates Hippocampal Damage and Aberrant Neurogenesis Contributing to Epilepsy-Associated Anxiety","journal":"Front Mol Neurosci","work_id":127128,"publication_date":"2022-07-06"},{"doi":"10.1093/rheumatology/keab918","pmid":"34919658","year":2021,"roles":["drug_mediator"],"title":"Secukinumab-induced systemic lupus erythematosus occurring in a patient with ankylosing spondylitis","journal":"Rheumatology (Oxford)","work_id":292278,"publication_date":"2021-12-14"},{"doi":"10.1111/bjd.20413","pmid":"33913511","year":2021,"roles":["drug_mediator"],"title":"Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate‐to‐severe plaque psoriasis: results from EXCEED, a randomized, double‐blind head‐to‐head monotherapy study","journal":"Br J Dermatol","work_id":289118,"publication_date":"2021-04-29"},{"doi":"10.4103/ijo.ijo_1081_20","pmid":"33120695","year":2020,"roles":["drug_mediator"],"title":"Role of secukinumab in ankylosing spondylitis with tubercular uveitis","journal":"Indian J Ophthalmol","work_id":293341,"publication_date":"2020-01-01"},{"doi":"10.1002/art.40581","pmid":"29869838","year":2018,"roles":["drug_mediator"],"title":"Brief Report: Interleukin‐17 Blockade With Secukinumab in Peripheral Spondyloarthritis Impacts Synovial Immunopathology Without Compromising Systemic Immune Responses","journal":"Arthritis Rheumatol","work_id":288606,"publication_date":"2018-06-05"}],"source_paper_count":5,"extracted_claims":[{"side":"drug_mediator","object":"IL-17A","context":"in peripheral spondyloarthritis","subject":"Secukinumab","work_id":288606,"claim_id":214074,"polarity":"positive","predicate":"inhibits","confidence":0.95,"extraction_run_id":29},{"side":"drug_mediator","object":"IL-17A","context":"in patients with psoriatic arthritis and plaque psoriasis","subject":"secukinumab","work_id":289118,"claim_id":216607,"polarity":"positive","predicate":"inhibits","confidence":0.95,"extraction_run_id":29},{"side":"drug_mediator","object":"IL-17A","context":"mechanism of action","subject":"secukinumab","work_id":292278,"claim_id":229571,"polarity":"positive","predicate":"inhibits","confidence":1.0,"extraction_run_id":29},{"side":"drug_mediator","object":"IL-17A","context":"in patient with ankylosing spondylitis and tubercular uveitis","subject":"secukinumab","work_id":293341,"claim_id":233805,"polarity":"positive","predicate":"inhibits","confidence":0.9,"extraction_run_id":29},{"side":"mediator_outcome","object":"neural progenitor proliferation","context":"in dentate gyrus after status epilepticus","subject":"IL-17A","work_id":127128,"claim_id":93335,"polarity":"negative","predicate":"correlates_with","confidence":0.7,"extraction_run_id":20}],"extracted_claim_count":5,"extraction":{"model":"deepseek-v4-flash","model_source":"configured","prompt_version":"v1_2026_05_07","run_ids":[20,29]},"bridge":{"a_to_b_predicate":"inhibits","b_to_c_predicate":"correlates_with","a_to_b_evidence_count":4,"b_to_c_evidence_count":1,"edge_support_log_ab":1.6094379124341003,"edge_support_log_bc":0.6931471805599453,"novelty_factor":1.0,"direct_a_to_c_count":0},"embedding":{"model":"bge-m3","dim":1024,"max_length":8192,"similarity_scores":{}},"scoring":{"method":"swanson_abc_log_evidence_with_novelty_penalty","formula":"score = min((log(ab+1) + log(bc+1)) * novelty / 10, 1.0); novelty = 1.0 if direct==0 else 0.7 / (direct+1)","score_raw":0.23025850929940456,"score":0.23025850929940456,"quality_tier":"mid","quality_reason":null},"pipeline_run":{"id":4,"run_uuid":"eb8b7730-d92e-4cd5-95dd-95f6c5d62cc2","command":"scripts/backfill_provenance_v2.py:v2_2026_05_12","status":"completed","git_commit":"9996ffaa56e9b7cd5f677bd8203624c2c18aa000","host":"MacBook-Pro-Daniel96.local","started_at":"2026-05-12T21:35:53.363326+00:00","ended_at":"2026-05-12T21:43:41.903387+00:00","notes":"Retroactive provenance backfill on 2026-05-13 for snapshot v2_2026_05_12. Synthetic pipeline_runs row — original generation run records are lost (pre-date provenance schema). All recoverable fields populated from current DB state (claims, works, repurposing_hypotheses); pipeline_run record is synthetic, hence completeness='partial_backfill'.\nBackfilled 1,618 provenance rows. Source papers: avg=3.73, zero=0. Claims matched: avg=4.09, zero=0.\nRefreshed 1,618 provenance rows. Source papers: avg=3.73, zero=0. Claims matched: avg=4.09, zero=0.\nRefreshed 1,618 provenance rows. Source papers: avg=3.73, zero=0. Claims matched: avg=4.09, zero=0.","domains":["als","alzheimer","depression","epilepsy","glioblastoma","inflammatory_bowel_disease","multiple_sclerosis","pancreatic_cancer","rheumatoid_arthritis","type_2_diabetes"]},"generated_at":"2026-05-12T21:43:40.945575+00:00"}